Low-dose methotrexate was not clinically effective for lowering blood pressure among patients without rheumatic disease who have cardiovascular risk factors.
The 2-year follow-up data from the FAME (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) trial 1 show that patients with coronary artery disease (CAD) undergoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback